DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1

Recruiting

Conditions: Advanced Solid Tumors
Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Interventions: Drug: Sotorasib
Drug: RMC-4630
Drug: Afatinib
Drug: MVASI® (bevacizumab-awwb)
Drug: Atezolizumab
Drug: BI 1701963
Drug: AMG 404
Drug: TNO155
Drug: Trametinib
Drug: Pembrolizumab
Drug: Palbociclib
Drug: Everolimus
Drug: IV Chemotherapy (Regimen 1)
Drug: Carboplatin, pemetrexed, docetaxel, paclitaxel
Drug: Panitumumab
Drug: IV Chemotherapy (Regimen 2)

First Posted Date: 2019-12-04

Last Posted Date: 2025-03-27

Lead Sponsor: Amgen

Target Recruit Count: 1200

Registration Number: NCT04185883

Locations: 🇺🇸
Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States

and more 87 locations

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Phase 3

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Apremilast

First Posted Date: 2019-11-25

Last Posted Date: 2024-05-16

Lead Sponsor: Amgen

Target Recruit Count: 160

Registration Number: NCT04175613

Locations: 🇺🇸
First OC Dermatology, Irvine, California, United States
🇨🇦
AvantDerm, Toronto, Ontario, Canada
🇪🇸
Hopsital Germans Trias I Pujol, Badalona, Spain

and more 47 locations

Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

Phase 2

Withdrawn

Conditions: Highly Sensitized Patients on Waiting List for Kidney Transplantation

Interventions: Drug: Inebilzumab+VIB4920
Drug: VIB4920
Drug: Inebilizumab

First Posted Date: 2019-11-22

Last Posted Date: 2024-06-21

Lead Sponsor: Amgen

Registration Number: NCT04174677

Locations: 🇺🇸
Reserach Site California, San Diego, California, United States
🇺🇸
Pennsylvania Reserach Site, Bethlehem, Pennsylvania, United States

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: VIB4920
Drug: Placebo

First Posted Date: 2019-11-15

Last Posted Date: 2024-12-17

Lead Sponsor: Amgen

Target Recruit Count: 78

Registration Number: NCT04163991

Locations: 🇵🇱
Research Site, Warszawa, Poland

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-11050

First Posted Date: 2019-10-25

Last Posted Date: 2020-06-22

Lead Sponsor: Amgen

Target Recruit Count: 44

Registration Number: NCT04139226

Locations: 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

Phase 2

Completed

Conditions: Sjögren's Syndrome

Interventions: Drug: VIB4920
Drug: Placebo

First Posted Date: 2019-10-16

Last Posted Date: 2025-04-30

Lead Sponsor: Amgen

Target Recruit Count: 183

Registration Number: NCT04129164

Locations: 🇬🇧
Research Site, Truro, United Kingdom
🇺🇸
Research site, Dallas, Texas, United States

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Phase 1

Terminated

Conditions: MUC17-positive Solid Tumors

Interventions: Drug: AMG 199

First Posted Date: 2019-10-07

Last Posted Date: 2024-11-22

Lead Sponsor: Amgen

Target Recruit Count: 58

Registration Number: NCT04117958

Locations: 🇩🇪
Klinikum rechts der Isar, Muenchen, Germany
🇦🇹
Landeskrankenhaus Salzburg, Salzburg, Austria
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 18 locations

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Phase 4

Completed

Conditions: Uncontrolled Gout
Kidney Transplant

Interventions: Biological: Pegloticase

First Posted Date: 2019-09-12

Last Posted Date: 2024-06-26

Lead Sponsor: Amgen

Target Recruit Count: 20

Registration Number: NCT04087720

Locations: 🇺🇸
Nephrology Consultants, Huntsville, Alabama, United States
🇺🇸
Amicis Research Center, Northridge, California, United States
🇺🇸
Coastal Medical Research, Brunswick, Georgia, United States

and more 5 locations

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Talimogene laherparepvec
Drug: Pembrolizumab

First Posted Date: 2019-08-28

Last Posted Date: 2025-01-07

Lead Sponsor: Amgen

Target Recruit Count: 72

Registration Number: NCT04068181

Locations: 🇺🇸
New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸
United States Oncology Regulatory Affairs Corporate Office, The Woodlands, Texas, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 43 locations

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

Phase 2

Completed

Conditions: Palmoplantaris Pustulosis

Interventions: Drug: Apremilast
Drug: Placebo

First Posted Date: 2019-08-15

Last Posted Date: 2024-07-17

Lead Sponsor: Amgen

Target Recruit Count: 90

Registration Number: NCT04057937

Locations: 🇯🇵
Research Site, Tsu, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy